Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2013 2
2014 2
2015 1
2016 1
2017 1
2018 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
Fucà G, Cohen R, Lonardi S, Shitara K, Elez ME, Fakih M, Chao J, Klempner SJ, Emmett M, Jayachandran P, Bergamo F, García MD, Mazzoli G, Provenzano L, Colle R, Svrcek M, Ambrosini M, Randon G, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, Corti F, Cremolini C, Overman M, Andre T, Pietrantonio F. Fucà G, et al. Among authors: elez me. J Immunother Cancer. 2022 Feb;10(2):e004001. doi: 10.1136/jitc-2021-004001. J Immunother Cancer. 2022. PMID: 35110358 Free PMC article.
Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E, Grasselli J, Argiles G, Elez ME, Tabernero J. Sanz-Garcia E, et al. Among authors: elez me. Expert Opin Biol Ther. 2016;16(1):93-110. doi: 10.1517/14712598.2016.1108405. Epub 2015 Nov 7. Expert Opin Biol Ther. 2016. PMID: 26549053 Review.
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer.
Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, Pietrantonio F. Nasca V, et al. Among authors: elez me. J Immunother Cancer. 2023 Jan;11(1):e005493. doi: 10.1136/jitc-2022-005493. J Immunother Cancer. 2023. PMID: 36593068 Free PMC article.
New approaches and targets in advanced colorectal cancer.
Macarulla T, Capdevila J, Perez-Garcia J, Ramos FJ, Elez ME, Markman B, Ruiz-Echarri M, Tabernero J. Macarulla T, et al. Among authors: elez me. Eur J Cancer. 2009 Sep;45 Suppl 1:79-88. doi: 10.1016/S0959-8049(09)70019-X. Eur J Cancer. 2009. PMID: 19775607 No abstract available.
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Pietrantonio F, et al. Among authors: elez me. J Immunother Cancer. 2021 Aug;9(8):e003370. doi: 10.1136/jitc-2021-003370. J Immunother Cancer. 2021. PMID: 34429334 Free PMC article.
A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.
Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J. Tabernero J, et al. Among authors: elez me. Clin Cancer Res. 2014 May 15;20(10):2793-804. doi: 10.1158/1078-0432.CCR-13-1837. Epub 2014 Mar 14. Clin Cancer Res. 2014. PMID: 24634378 Clinical Trial.
A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.
Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG. Puig I, et al. Among authors: elez me. Clin Cancer Res. 2013 Dec 15;19(24):6787-801. doi: 10.1158/1078-0432.CCR-12-1740. Epub 2013 Oct 29. Clin Cancer Res. 2013. PMID: 24170545
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.
Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R. Santos C, et al. Among authors: elez me. Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16. Mol Cancer Ther. 2017. PMID: 28626084 Free article.
12 results